Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health and Family Welfare has given emergency use authorization approval to COVID19 vaccines Covovax & Corbevax and Anti-viral drug Molnupiravir, said Health Minister Dr.Mansukh Mandaviya on Tuesday, according to ANI.
US biotechnology company Novavax’s protein-based Covid-19 vaccine, NVX-CoV2373, is being locally manufactured by Pune-based Serum Institute of India under the brand name Covovax. Corbevax or BioE COVID-19, is a COVID-19 vaccine candidate developed by Indian biopharmacutical firm Biological E. Limited (BioE), the Baylor College of Medicine in Houston, United States, and American company Dynavax Technologies (DVAX). It is a protein subunit vaccine. Molnupiravir is an anti-viral drug that is made by American Pharmaceutical Company Merck & CO. This is an oral drug.
The Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) has recommended granting emergency use authorisation to the Serum Institute of India’s Covid-19 vaccine Covovax and Biological E’s vaccine Corbevax with certain conditions.
The panel also recommended granting permission to manufacture and market anti-Covid pill Molnupiravir for restricted emergency use for the treatment of adult patients.